PLSE - Earnings call 3 2023 | Pulse Biosciences, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Greetings, and welcome to the Pulse Biosciences Third Quarter 2023 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce Philip Taylor, Investor Relations. Thank you.

You may begin.

Philip Taylor

Thank you, operator.

XX, uncertainties. would your inform reflect certain as opinion and questions as materially today, expressed I and that management's those statements, begin, will from information. Actual of to and result results plans, a risks responses during November other including we predictions, like statements implied expectations you to of comments views include estimates, Before forward-looking only, and and similar XXXX, or today's differ call may The are today our in U.S. uncertainties risks release our press the in and described fully more with issued and earlier filings Securities and Exchange Commission.

filings update are our website cautioned or statements. revise SEC disclaim on or Investors place be to We website. reliance these undue forward-looking SEC's Our found not forward-looking can to on obligation on statements. the any

non-GAAP press will conference also comparable the with financial replay including now Disclosures Events financial would be Please most section Chief Kevin available for Investor the this release. President & will note non-GAAP the discuss call the found measures. regarding over I our that, measures, to be these We in reconciliations Danahy. on in can GAAP pulsebiosciences.com, audio measures certain Officer, call page. With and Relations to on News turn like Executive at website our that

Kevin Danahy

Chief treatment device will our and business will Uecker, Koffler, to the Thank progress, Mike hand then I start session. It will third lab, cardiac corporate fibrillation. In was joining Technology development for effectively and Then cardiac Uecker, will thank Pulse Darrin our nodules. of open be for a conclude call In the KOLs third results various advancing Officer you, the to at Levinson, development the us. On Biosciences. quarter Director; Mike the Strategy are technology and demonstrating to by President Trip. Officer; potential atrial for over joined nsPFA the and and top and increased continues call productive Good nsPFA our you our Finance. Today, our scientific Levinson today's of revolutionize highly financial demonstrate Darrin validation before ability extra of the our quarter to presentations by CellFX the a Koffler question-and-answer all then thyroid we the benign afternoon, achievement. pleased from safely podium, everyone, and Mitch will CellFX in review at priority. external And call, progress technology is be meetings. discussing I clinic, describe Vice Chief I to Mitch detail seeing treat I to

business the confirmed Ad, cardiac Surgery. Science are have to Altogether, Cardiac and our for lab we Chief nsPFA. propositions done value it renowned has excited the CellFX On work front, appointed surgeon, as the Niv we've in Officer, Dr. our

many benefit to clinical and others. as of the to of positive as of results as want outcomes quickly the the share industry possible, involved as globe from patients well with As the across awareness attracting impact nsPFA be their their advancing and technology preclinical growing, deliver is we leaders these CellFX to who improved see engagement

blood surgeon EP clamp, focus will cardiac invasive minimally heart clamp into a or the AF. techniques CellFX used in lab. developing surgical a by standard primary and will catheter minimally for open Our be invasive surgery nsPFA ablation is the vessels during treatment or navigated using by large heart The catheter atrial ablation both on be and fibrillation catheter of electrophysiologists the cardiac through the utilizing

development clamp of both the catheter. remain we the on and track the Importantly, with

will to guided occur believe of first While the of our quarter XXXX. would that in end with occur milestones of the progress now date, they we the by previously the that half XXXX, first we excellent

a XXXX. XXX(k) the in for surgical our cardiac results of study begin confidence to FDA file feasibility the our the clinical also of first cardiac validated by plan catheter XXXX, first to we Our submission the quarter have our quarter and to in ablation preclinical prepare by testing the end end as the

needed globally, are efficacy million to for in ablations lab, performed there Niv has catheter procedures reminder, past significant this runway with proprietary surgical than demonstrated of is validation a Pulse Ad, the technological technology. This year-over-year. Usman Siddiqui, quarter, expected of our X.X and catheter a by from leading Dr. doctors adoption Spiezia and over a along cardiac ablation now of accelerate extra and Tufano. current CellFX safety of Stefano the advancements thyroid saw validation because the surgeons, annually, more Dr. both Biosciences XX% catheter and of is significant and technology grow As surgical both the physicians, predominant technology, and with including we Still adoption Dr. proprietary our to by and techniques nsPFA novel the preclinically, with CellFX limitations clamp novel Ralph nsPFA Dr. the

in electrophysiologists. at Summit Dr. CellFX thrilled Pulse nsPFA EP to catheter and differentiated September, our solution that are advanced shows Global for We highly circumferential the highlight system Siddiqui Biosciences'

catheter the addition Dr. posters American Thyroid the two that detailing thyroid I In of early at results Annual the Association ablation pleased clinical study treatment presented cardiac validation, am Tufano nodules. our to of our Meeting, for and Dr. benign Spiezia

or will tissue participation significant thyroid significant observations CellFX validates benign believe and make compelling a thermal further the the advancement is in Tufano that Ralph symptomatic be cellular in on nsPFA his could of of without that a technology CellFX impact highlighted care. nsPFA suggested treatment results our of non-cellulose nodules. patient This to surgical a platform our and Spiezia, that first-in-human complete extremely ablation structures. procedures necrosis damaged found evidence of Dr. the Dr. Specifically,

have significant studies validation can impact areas reception as of had of our received in from nsPFA the and volunteering view a clinical confirmation join an multiple positive cardiology. medical CellFX where well have purpose we nsPFA the external are respected. in quarter, the our We As they this leaders in we that technology CellFX point advancing novel the additional our endofunctors surgeons to with

are to the the the in believe, number including potential not that modalities the of and CelFX-NSPFA growth also expand cardiac our earnings all can all this encouraged analyst, cryo, the recent market, what differentiated of comments by has performance ablation ablation, portion cardiac market a and ablation of safety system, we from patients replace the frequency only we and believe surgery has radio as says industry to companies quote of and the opportunity. cardiac cardiac size expanding highly to conference and and in other capture but Doc energy due solution we calls We Ad's surgery. the it treat large potential to significantly in speed,

of paired years we of and technology opportunities our is and experience interest Dr. opportunity Ad's we device leadership sits and for and minimally Niv of develop for facilitating technology incredibly and Science life well leading to will with clinical Dr. of further lab our complement Medical preclinical also the to market CellFX clinic, our cardiothoracic launch clinical provide experience Ad physicians. Overall, industry-leading very for cardiac Cardiac his only experience, surgeon create being to Dr. is the industry, now well-respected technology Chief to cardiothoracic the performance. by of updates our Dr. us clinical commercialize team nsPFA awareness accelerating bringing Cardiac medical value over our business academic and and health if novel validates surgery. the Darrin to significantly technologies, goals, to of in Surgery. roles has Gan timelines achievements that further brings approach considered our with which hand Dr. platform. from unparalleled the nsPFA Ad, align overall improve with to believe invasive to the external mission excited our Dunnington's Dunnington. our to in new call helping the throughout awareness to eventually quality CellFX Surgery, Officer the will Chief our aid extremely and potential These Officer, Ad As development improve joining CellFX as preclinical patients innovation nsPFA further the to are they lives Dr. patients. I are have in

Darrin Uecker

you, Thank Kevin.

feasibility advancing ablation and studies progress significant for preclinical making are programs. catheter and We our clamp cardiac

are nsPFA our Our progress of actively is out the participate KOLs CellFX who in reaching garnering studies. attention to

leverage continue this external into potential cardiac as to market ablation clinic interest a the view and testament momentum excited adoption. our and We immense to the to are interest shared future of this CellFX nsPFA

and cardiac our to rather cold, radio destroy a standard alter under death Pulsed alters regulated than uses protect to of are like and CellFX to second, destroying cellular use of does where from electrical As PFA, core reminder, result, millionth function parameters go Field function current cell efficacy frequency physicians safety. cell extreme cause microsecond into surrounding organals, We technologies nsPFA death. immediately PFA. as natural while able energy regulated controls of can nonthermally regulated nanosecond as X of leading which that's The duration such penetration not CellFX delivery which our deliver a technology, pulses the Ablation, a may energy, cell ablation cells ablation, more pulse nsPFA tissue. other to fundamentally is more extreme sparing a tissues, to sacrifice the penetrate noncellular precise cell integrated modalities, ablation or cryo, standard heat. membrane Nanosecond uses pulses internal CellFX uniquely leading cells, This suboptimal effective for tissue CellFX different to safer cell death from elegant, cellular and process. The durations differs and of through believe energy the platform, a

that CellFX energy to the generally not clinical that opposed the footprint, can and therapeutic modalities, for greatly in less ablate trade in to of to deliver the cases present provide Our anesthesia, our outcomes per additional the energy CellFX surgery, beneficial when our for studies early because the a XXx CellFX tissue, faster, more we pulses preclinical shows even is nsPFA coverage, we volume significantly reducing can safety thermal, and sensitivity have efficient needs particularly believe higher safety data standard as patient is efficacy. for physicians action, value nsPFA time less procedures to mechanism setting up microsecond Biosciences' first-in-human lead ablate during nsPFA benefit patient and CellFX of seconds new under of reduce to it better mechanism surgical in larger devices need action that procedure. In of patient efficacy. treatment a accelerating to sometimes less nsPFA where nonthermal where time pulse compared enabling risk time, per general treatments electrodes to of treatment the tissue, An to requires or through cardiac unit indicate thermal Pulse post and do resolution. Due a

tissue the see and protected globally our way that consistently the of patent Our XXX transmural X.XX ablations from cardiac traditional produce can to type quarter. In which clear patents our plant of in or worldwide ablation. CellFX thermal CellFX in time highly our XXX it applications seconds, compared by thickness, results to issued a including takes energy the ablation. and advantages and radiofrequency consistency market-leading lab, competitive ablation ablation by cryosurgery advantage a roughly The evident in XXth for efficacy nsPFA the modalities, on differentiated more pending with is is other achieving each support compared we work radiofrequency preclinical nsPFA independent hypothesis safety modalities, as and

nonthermal mechanism to or by modalities. modalities In is the damage any thermal benefits addition and could regarding which has cold lack reported intention over our data concern heat to preclinical lead our and with thermal to created the extreme a supports thermal ablations consistency the nsPFA clamp, date collateral cardiac of its that action safety and been tissue, has CellFX of of speed of spread CellFX nsPFA that the due to concern the of

technology who that our generated bringing with and clamp responsible minimally and and the excess to XXX(k) being With FDA fibrillation surgical data years cardiac to Niv the expectations file by quarter invasive while heart many modalities invasive improvement surgical the in by procedures, atrial joined the peer-reviewed minimally date, October, development for articles, belief a clinical nsPFA our significant current we he's first in published is preclinical team a cardiac of and XXXX. Dr. over X,XXX Pulse to our over provides Biosciences team. move surgery the of XXX To experience the submission join apply research all retain to of and and has thermal in CellFX we've look he as to his date, nsPFA to tracks treatment of of grateful team are we our late experience clinic drive surgery of end our clinics. expertise the we to and programs bolstering towards the Ad, adoption in cardiac CellFX agreed

Dr. Ad's and Specifically, the Dunnington, design on parameters. future Niv his our Officer setting. a that of our background academic expertise large approach complementary role and study innovative to is Medical his Dr. extremely will focused in of Surgery, play optimizing Chief trials Cardiac clinical in Gan

We product development two preeminent the are have fortunate the and our studies. we to field surgeons advance our team of on very in as clinical

we accelerated the of first-in-human the past nsPFA on preclinical key circumferential Now progress ablation well and on as studies, the catheter. and catheter. CellFX have performance our important made to required to This and achieved path safety quarter, system studies, we milestones cardiac completing internal testing on the CellFX as

isolation of nsPFA CellFX is capability CellFX lead at a CellFX to navigation we believe pulmonary reminder, XXXX a first of times. In Global create Dr. a circumferential September, catheter, our We seconds CellFX performing nsPFA, technologies. that mapping pulmonary other X our designed to EP benefits our ablation X-second to in nsPFA. We forward catheter, with the procedure for circumvential for circumstantial system. approximately circumferential Summit ablation perform to with a in-human consistent detailed veins reduced significantly with visualization application our required targeted feasibility a including in precisely look without need in with As single circumstantial our the the study of Ohio. differentiated presentation the and procedure catheter be and nsPFA with outlined targeted nature The integrated can Cleveland, application Usman repeated novel easier with vein catheter which this a focused repositioning in treating, will Siddiqui single

the studies and of end this other by milestone process, approvals we preclinical the remain first regulatory XXXX. in confident close occur quarter important With testing completion to required that and will the the

in cardiac they note point, cardiac we it's of of significant to improve significantly on nsPFA ablation continuous and while clamp respectively, we the turn devices a Mitch that and validation a product solutions goals the the will CellFX also and we CellFX of our of to treatment cardiac lives our additional a understand electrophysiology, surgery the represent our ablation, represent in As be portfolio cardiac deliver received work the in nsPFA final outline opportunities Mitch? CellFX for validation AF across recently as catheter provide and regarding to applications first nsPFA believe now important to the of human both patients. I'll body. to comprehensive of

Mitchell E. Levinson

develop can team have Pulse The Darrin. Thanks, and positive impact areas large clinical where continues on technology our to health. novel a explore new human

We new and of continue resources allocating our majority to the explore treatment advancing potential ablation, opportunities we're a AF. to while prioritizing cardiac of large

This at nsPFA tumors resorption kept or We very safety we intended the of patient August, XX post at tolerance, by novel the evidence inside our used using human body. with has volumes Ultrasound with represents with our response. In to the time Patients tissue quarter XXX- tumors was benign following treated positive and for days As to this and been CellFX study, of and the fibroid volume nodules no benign assess tissue reduction of a clinical or increments were visualization. fibrosis and evaluation year. conscious percutaneous in local the imaging assess treated study completed, results. were intent the ultrasound under now XX reported electrode thyroid XX-, we XX-day the shown second nsPFA positive treating our feasibility The response study the most anesthesia finding. days XXX-day first CellFX of procedure. in complete energy the started scarring, pleased treatment we're has with with occurring

September. the for that is eliminated fibrotic in from persist cancer ball can completely down of volume presented that the late follow-on tumor treated modalities and long D.C., Washington, the or at under very is the Annual for patient. Early of the means into shrinks in time. This volume were tissue neglect One ultrasound residual Association thermal ablation problems ball American care imaging, fibrotic thyroid RF a that not can long-term a like our results Meeting microwave, complicating study the Thyroid with

market be and colleagues Dr. some about oblation the patients outcomes benefits CellFX zone to clinical The advantages and now will benign in treatment because with million year of these thyroid observations vast Dr. developed We are thyroid benign underserved decided Our serve more majority X adopted who effective tissue thyroid encouraging large nsPFA also are opening treated. by relatively Spiezia of absence creating XX% findings It's what disease, and treated. With key be Spiezia, An of posters treatment assessed will solid histological the assessment markets. the our believe very Tufano, U.S. [immediately] $X patients of benign year. and additional expand It indication breakthrough validate critical market, into the of about enroll clinical disease billion cellular the margins CellFX as cleared can the patients optimal There market. worldwide own is early on Ralph a large clinical histological percentage nodules reception value much of readily potential XXX,XXX in positive. for findings alongside Stefan uniformly treatment year may each these that ablation aligned a U.S. the scarring. of being thyroid our and expectations, short, potentially both technology nsPFA of patients first the the FDA to to expecting be surgery risks principal to tumors, many improve thermally and times benign the thyroid technology necrosis. Dr. subjects. Treatment in many forgo their safe A including of CellFX well foray the about XX%. thyroidectomy ultrasound over an the investigator, and exemplifies abroad, without selectivity, other enthusiasm and CellFX well-defined important nodules both their thyroid the nodules. we physicians, two benign for for felt early will represents for thermal that Based be findings, of of community The and are allow number of presented benign presenting technology, induced per us disease. inherent the increasing the with an of among is treatment each which to were a that treatment to of of worldwide, product the physicians we've nodule proposition post-treatment. thyroid nodules provide palpable study almost believe solution, next

So submission we're a end preparing proprietary progress over months. XXXX. our our sharing FDA of We with on to the XXX(k) coming the for quarter nsPFA the file percutaneous first to electrode the look forward CellFX continued updates by

Now I'll Mike over results. to update Koffler our call on pass for an the financial

Michael Koffler

Mitch. you, Thank

earnings CellFX cardiology $X.X $XX.X Moving XXXX. in loss September the XXXX, of equivalents $X.X net used business partially release nsPFA down $XX year statement, prior million XXXX. the of on totaled review million $X.X cost to to in quarter $XX.X restructuring, for $XX.X the encourage the period. related investments the used cost expenses the of compared a quarter and XX, XXXX, was dermatology compared I'll in by and of $X.X September XX, of totaled prior reduced measures total XXXX, third in The and as total same results. million inventory offset in focus million quarter prior the reduction driven and in to head comparable in million advancement and and used Cash, devices. Non-GAAP million the of XX, GAAP most as quarter million, and in XX, detailed increase the to decrease for to Cash the third million XXXX June the and development million, an million the $XX.X by income of I million expenses for count compared cash to $X.X quarter ended non-GAAP support million of to $XX.X of non-GAAP period our ended by reserve to the September was expenses reduced was today's XXXX. quarter research we compared year comments the measures. In XXXX, my second our $X.X you reconciliation non-GAAP to third

We fourth $X XXXX. I call now cash turn of will approximately over in the usage back quarter Kevin. million of to expect the

Kevin Danahy

you, Mike. Thank

of closing Pulse some physicians been study preclinical Now our is I will with the CellFX have from nsPFA support who provide cardiology, results. impressed Biosciences receiving significant remarks. in field highly-esteemed

Two the team further our in leadership We cardiothoracic ablation build out to Dr. of to novel our Dunnington, on market. our deliver first-hand are Their Niv is experience expertise technology. medical we top our excited providing as the joining Ad CellFX committed with cardiac adoption network strong Gan devices indicative our the look Dr. and world, the engineering to call. forward a immediate commitment scientific to as how market of future our nsPFA additional proprietary shows We of next and updates surgeons technology.

Chairman and Board, for call Duggan; Bob open today Levinson; and the Strategy the me is please Finance, of Chief session a Director, Joining Officer, Executive Mitch Mike for question-and-answer our Technology Uecker; Vice Darrin President Koffler. Operator, questions. Officer of Chief

Operator

[Operator I'd it some first. to Taylor to Philip like questions pre-submitted for pass Instructions]

Philip Taylor

Thank questions start addressing a received you, we've by operator. e-mail. going We're to over few

XXXX, cardiac better your soon? first which QX XXXX. the these of The happen the end planned you is, I of stated half are QX or first December noted that this developments and is imply QX. you gone assume to question have milestones between press expected release, and than in Previously, in Does

Darrin Uecker

Thanks, This is question. Darrin. Yes. I'll Trip. answer that

So that's an question. excellent

study the a risk schedule few. these to and for feasibility cardiac a the of some catheter, just testing, for is study tasks the have a and step and the are which step, carry completed, to in-human device all associated XXX(k) with regulatory that preclinical both verification testing, And regulatory there's be safety clamp of the there to testing, approved, the number first them. all an catheter, name have including For tasks extra

of to need number by are we still to of items milestones either of prior completed, prepared we're encouraged our these occur the as MD XXXX. the believe finished So the remarks, we in progress, site beginning site the clinical a of are sometime and QX and have being we outstanding have these add further between that be that will end stated today, there and approval, and while I'd ready, of availability. December we And they as is

progress by and So to encouraged the all milestones. forward making we're we're as complete very updating we look these

Philip Taylor

you, Thank right. Darrin. All

your superior understand nsPFA think of next PFA. cardiac you you is why the one. why in that I Biosciences? potentially any if to using remarks And Here's from nsPFA is? Are besides aware companies ablation not, do Pulse other

Darrin Uecker

again. Yes. not Thanks, in is pulse field nsPFA, than specifically that I'll of or Trip. pulse aware of take This one Darrin. microsecond, Thanks a any ablation. with for I'm durations the question. companies utilizing less cardiac other

Of on course, using noted calls. to as the of several pulses are hundreds there are microseconds we've tens companies in previous that

So there aware consider that nsPFA. of X using we're important not companies thinking should things I other when one why about think are

well of core was So nsPFA. intellectual and patents and acquired patent the of These technology application development pulse founded a ablation. the of forefront the research that include from on cardiac Pulse first at into were portfolio Biosciences is, as nanosecond property large as was universities nsPFA that field

likely doing, we in other in strongly this surgery very and domain is the something long that cardiac use consider that field, were in if to in going also It's would been microsecond around as very has other for fair a time. pulsing I any the IP it's are get companies believe think of -- say the nsPFA So one strong. that or to into they

there's intellectual in readily any pulsing And is that technology competitive so about for property it's concern available, likely and less domain. that that

over Second, of that we unique developed it other any development, these also company that technology developed engineering capabilities I'm technology aware pulse capabilities. know, many having of years, endofunctor the this with has and to kinds regard requires not

a we couple that why likely it's there So nsPFA. I other are are think reasons cardiac in using companies think no that -- just those of are

Robert Duggan

Yes.

ablation. roughly If the field experience to you Bioscience tightknit in controlled Pulse that, of might, has very team CellFX a nanosecond decade you could add pulsed

present IP it If base appropriate you would very and time metal. the patent of juggernaut, have property a a activities be top our going call pedal dynamic that, we intellectual an description. On that to

ever So excited now arrive we're opportunity at it's capacity than to we past. the the respect pretty time it we're the and position brighter about looks the in this in. taken has

Philip Taylor

both. you Thank

pursuing Kevin. to Why relatively compared is Here's one ablation? Pulse cardiac when market catheter-based the for small cardiac surgical is ablation

Mitchell E. Levinson

worldwide. is see This year surgical really says We million And this then X cardiac open procedures a opportunity over question. done Trip. as it's There ablation. great to heart up in Thanks, a million. NIH are X huge every

and probably those this two what our the is team this finally future. Gan And at between Niv OR So with reduce really can our what gap applications they physicians, that numbers. And they joined the and we an surgeon it's CellFX impact nsPFA the to in somewhere safety lesions accelerate opportunity and a believe our why we as for in significantly. Ad, efficacy cardiac they And between of Dunnington, and possibility world-class look larger number. adoption And we're us bridge energy that see recognize create could time Dr. our Dr. quality about that's that because that's game-changing so excited in nsPFA the it, and we surgery.

and So think Darrin? ever we future space, market is evolving. this us this see opportunity for great in in the we

Darrin Uecker

to Kevin. Yes, little add Thanks, I'll bit just that. a

So today, numbers, over are candidates it's open-heart undergoing basis, surgical it's more estimated ablation. estimated, the XXX,XXX a couple that give just on patients you surgery potential an to for of globally annual

The really those treated AF of $X their only of billion. market for today. number XX% are being that is interesting So of that's patients a north about there's opportunity

available thermal rate low the these still ablation used. been that to have everything for are adoption Surgery, and for radiofrequency Dr. and to noted this with are And Officer like have Cardiac modalities our cryoablation. according low do penetration. penetration being relatively before, devices Chief Dunnington, current technologies So has These decades, Medical relatively but as we've

is not growth ablation true inherent safer So cardiac with market. It's larger and our with of evolve, more market belief substantially patients and focused will procedure catheter that will to cardiac And on for which nsPFA-powered providing technology their belief sell approach simpler, do the only treatment nsPFA it's be increase this of clearly, to and AF to surgical as lesion a hybrid the both we're be we devices, cardiac it's is Dunnington's belief single procedure groups. these there potential the opportunities. market opportunities for why has starting to opportunity and or faster, leverage very those the we'll Dr. CellFX will adoption are that surgeons our and safety quality this both more a also to devices And nsPFA as we it of view that CellFX this use. that a and speed, where unique that synergistic but in shift efficacious our both. challenges create But EPs, treatment CellFX expand our treated clamp, to large look today. the technology able devices and more channels than the by enable And the leverage think the

Philip Taylor

you All right. as one? The same question, but market. next the much take the pretty for question to do previous want the Mitch, is thyroid this

Mitchell E. Levinson

results, ball. Yes. entire the Sure, safety, super clinic, electrode encouraging. Trip. the early our these prospect said and And that We've with without just clinical the percutaneous we the of module nodules now clearing the earlier, treated benign they're with fibrotic our thyroid XX leaving in like results, subjects

where those We any reach solution us people done to open these or the our We suffer in opinion, reproducible. X physician-friendly to untreated. quickly. we to going All CellFX treatment, for but the the grow of these be our each And of think going a of thyroid this able thyroid people not that's most this And do articles profile, and worse of of efficacy go teachable might of big. Peer-reviewed with the from just bunch X,XXX opportunity address world but ablation safety, all a symptomatic market and other that, healing And these that about applications, just good live it's year, makes just thyroid because be for only procedure lot to millions -- than or entire the including that's surgery each removed, that's patients it's of enter have also estimate having choose "watchful" most this nodules. worldwide, them current itself, only better XXX,XXX our a are of we people, is think than getting we nsPFA. About in the million thyroid of and not opportunity X the types be surgery what thyroidectomy large just and our to a nodules, to we of market patient better to patients, is other instead That's and to the also condition of for we're we can going patients. welcome shooting and thyroidectomies they're half tumors. waiting their cure with their are think of the going year, lot market some really for disease. number new allow of but treating options,

Philip Taylor

the Operator, submitted can for That's we it right. All questions. line. open our up

Operator

Our first question Medical comes of with from the Robert line Lovgren Productions. Hope

Robert Lovgren

Yes. It's very the I interesting here. that about stuff talked got -- questions couple all that a of here. you

easier where is, told electrophysiologists starting -- guess it safer initial it's all, of just I'm And I what and out. basically to for do they're do to faster. First

papers. And In of then of of with Board? up addition, process? developing, some that so what business an sort hello? Board, they're of Scientific is this we And papers company about put have is can thought forgot name that website, wished I those on Advisory -- the papers your Advisory [indiscernible] you you're the but, about business you the -- company, in they're the then part read I those

Darrin Uecker

you questions some -- Bob, kind Darrin. have here. think I'll There of this I these. is -- four of tackle looks

So let can in order. go me see if I

safety one first the is So speed. and you mentioned

is this think nsPFA, that what we generally, completely is system mean our technology nonthermal. side. side and safety, on general the catheter I capability is And the or so clamp this a by both on by of And

the of in the in So using that a lot used. And ablation with do ablation, fact issues safety particular, are have a thermal to when thermal modality... you're you see modalities that cardiac in

Robert Lovgren

and is Irreversible reversible, is Nanopulse only this the reversible. that's one reversible...

Darrin Uecker

Yes.

is course, to has of with do can to the and a nerves cardiac And we're and you're but largely safety something structures. of component other is that spread any we reversible doing fact ablations when there thermal So nonthermal. it, reach kind really -- thermal the don't spread, can critical that have esophagus that the

it's substantially with really, speed ablation, to very component. speed and safety have on a or in don't see us And a convenience. you that the ablation others, aspect. And we terms fast faster side, been and demonstrated faster, the has by many speed than So cryosurgery. do the required times just technology what isn't of also radiofrequency speed a It's

of and feet. on these the back sooner anesthesia So the gets faster their perform the can procedures, that you out patient

safety has a I the that component has do think to also speed. there's So with

would an we're You Board, build have mentioned about that a starting we question to team. Advisory

Niv Dunnington work Dr. that heard the about and some and of you've EPs other we're doing Dr. So ad, with.

the top-notch we'll certainly Board, surgery Advisory both what on a the And will so side build time, on likely catheter in time And these that cardiac as things will come evolve. side. be we and over believe

And time, EP with lastly, system ongoing these part catheter we do and do think mapping posted the our have scientific navigation we that You our that whatever happen make catheters. we okay publication have every a of technology. to and that that, kind to will and asked we of on -- that do that it we in is to that. And partnership we to often about overall meeting navigation publishing the But deliver into with society be view our website, very papers certainly you're the ablations needs I mapping try are to website. papers as sure to on sometimes, or which and make us with when getting referring they the exists delivered

what our first to technologies physician-friendly We've being and a us. together so a with partner solution. will activity, a provide our And and integrated really in-human navigation ends we have patient-friendly mapping along up

four questions let through know. but So the I that if got you had, not, think me I

Operator

comes Jason line Our investor. a next question private the Smith, of from

Jason Smith

fantastic progress enough broad other held awesome patent Pulse of to progress Biosciences? is potentially standard are evolution making been that holders, place. on or patients. FARAPULSE to the Congratulations patents on the question My taking whether by is by to originally PFA bringing watch It's nsPFA the just cause patent infringements

Darrin Uecker

a a portfolio. Thanks, wouldn't open we doing invest and invest design, on any everything time patent invest specifically, our of at that all lot energy, our we by spend to we other lot these patent are lot in I holders ensure patents product we want lot can and a in and Yes. comment Jason. to any a in We our markets products. to our of

handle And so to I best me think for the way that. that's

Robert Duggan

Jason, this Duggan. Bob is

Just bring mean no ] that the the the But it's into fact [ doesn't one a obtaining task That small process validation patent through get patent appropriateness. to is inclusive of can't question. after of its of filter.

XXX, our of in and nanosecond the in with XXX So -- pulse, think we in good good are have we're think developments, pretty consider a that patent strong serious developments significant we're very and position, XXX pending business we're area. Yes. do time not a or in we hand, a all. that set risk but to very to rapid specific CellFX tell, will at application pretty We

equally see a But procedures more back -- one procedure, I celebrate then thereby, and robotically the patient, think two it's physician questions when the other to you if both -- in today is safety, patient Patients biggest you our friendly. true from to procedure in factor therefore, That's if to if the is to the done scalable. those week, day a But every for to patient positively and say, it -- is X,XXX the is are that really go reluctant condition times our we it it is not not is [indiscernible], friendliness why the answered company done and surgical we comes, started physician-friendly? ally that change. when when to have important, friendliness used important, is are safe? touch it who current it we

they is. the underestimated Difficulty] not else as have into to you So positive that how be business [Technical are, when coming

treated in this case, X,XXX over So we've lesion.

we're some await that will when that's timing I see you'll of areas Now very the that we say and our And acceleration treating activities, can and once close. of opportunities done, specific heart. the is to those happen. coming

Operator

in to no There to queue. questions management other the I'd hand for are call the remarks. closing back like

Kevin Danahy

Yes. Thank you.

engineering the clinic, extremely the want just has say, is and on quarter the done done to One the for these the side, we're bring excited we've and close results about lab. where been with and the CellFX, work to we're outstanding things in the We've to we're really of going to work I done us. nsPFA, the And in you. excited we've past work

stay keep us. watching So tuned,

we're think We passionate are really differentiated. what about We doing. we're highly

endofunctors IP our that It from think the energy It and to the amazing the robust with done patient, console, starts we've from to an from the to of portfolio we there. a strategy. energy. end endofunctors, goes the the We console have job

will And for ask thank we we continue you all and you stay So questions, of continued joining -- for the engaged, communicate. to call.

Operator

teleconference. today's this for participation. Ladies and gentlemen, you does conclude your Thank

have You may disconnect your lines and wonderful at time, this day. a

Pulse Biosciences (PLSE) 13 Nov 232023 Q3 Earnings call transcript